Eton Pharmaceuticals Director Norbert G. Riedel Receives Award

What Happened Norbert G. Riedel, a director of Eton Pharmaceuticals (ETON), was granted 10,000 performance‑vested restricted stock units (RSUs) on July 31, 2026. The award is reported as a derivative grant (Form 4 code A) with no cash paid (acquisition price $0). The RSUs convert to shares only if a market condition is met: the closing price of Eton common stock equals or exceeds $72.36 for one trading day prior to July 31, 2029; if the condition is not met by that date, the award is forfeited.

Key Details

• Transaction date: July 31, 2026; Form 4 filed August 4, 2026 (timely within the two business‑day window).
• Grant: 10,000 performance‑vested RSUs; acquisition price reported $0 (derivative award, code A).
• Vesting condition: closing price ≥ $72.36 for one trading day before 7/31/2029; if unmet, award forfeited on 7/31/2029.
• Reported shares after transaction: not disclosed in the provided filing.
• Footnotes: the award represents the right to one share per RSU; the number reported is the maximum issuable and there is no range or separate target.
• Filing remark: the reporting person authorized a designated filer to submit the Form 4 on their behalf.

Context This is a conditional equity grant to a director, not an open‑market purchase or sale. RSUs are a form of deferred compensation and do not result in immediate stock ownership until the vesting condition is satisfied. Such awards are routine for directors and are informational rather than a direct trading signal; purchases or sales tend to be more indicative of immediate insider sentiment.